Kissondra Morris is the Oncology Protocol Review Committee Lead in the Clinical Center of Excellence at Bristol Myers Squibb, where she oversees the scientific rigor and quality of oncology clinical trial documents. With over 10 years of experience in drug development, she has held roles spanning Innovation and Digital Health, Study Optimization, and Trial Digitalization.

At BMS, she has partnered across functions and with external collaborators to introduce new approaches in RWD and trial innovation that improve study design, streamline site technology, and strengthen patient experience. Earlier in her career, she held research roles at Moffitt Cancer Center, the University of South Florida, and Intezyne. She holds an MBA, an MS in Biotechnology, a Graduate Certificate in Intellectual Property, and she has contributed over 4,000 volunteer hours in healthcare and environmental projects.

Gaurav is a co-inventor of Piezo’s novel platform and founding CEO of Piezo Therapeutics. Prior to Piezo, he’s served in a variety of roles at Moelis and Company, Capital One, and Elevance Health. He’s a published scientist with a background in drug delivery and synthetic biology. He holds a BS in Industrial and Systems Engineering from Georgia Institute of Technology.

Dr Shawn Fu is currently the Head of CorpDev and Strategy at SonoThera, a venture backed non-viral, ultrasound based gene therapy company. Prior to joining SonoThera, Shawn was a Vice President at Vertex Ventures HC focusing on platform technologies and genetic medicines where he led investments and held board positions across both biotech & medtech opportunities, including, among others, SonoThera, Allay Therapeutics, and SpyGlass Therapeutics. Previously, Shawn also served as Vice President on JP Morgan’s Equity Research desk covering large / SMid Cap Biotech.

Dr Fu obtained his medical degree at UT Southwestern Medical School and his bachelor’s in biology/economics at Duke University.

Jaspreet Arora, PhD, is currently the Director of Business Development at Seran. He has 8 years' experience in drug product development with a recent NDA submission and approval for Leqselvi (Deuruxolitinib). He has early to late-stage experience including commercial readiness and IND/NDA writing. His oral solid dosage form expertise includes formulation and analytical characterization with a focus on material science. Previously Jaspreet worked for Concert Pharma (acquired by Sun Pharma) and Lonza-Bend (Bend Research). Jaspreet has a PhD in Chemical Engineering from Tulane University and a bachelor’s degree in biotechnology from Panjab University. Jaspreet applies his technical experience and training to understand client problem statements and support tailored solutions that fit clients' needs.

Yogev Debbi is the co-founder and CEO of Mana.bio. Previously, after working for years at the tech industry at Intel Corporation (Nasdaq: INTC), he co-founded and was the COO of Genome Compiler, a software gene editing company which was acquired by Twist Bioscience (Nasdaq: TWST), where he then led Twist's Israel R&D center through its IPO. Yogev brings deep expertise in launching and scaling successful bioengineering startups. As a repeat entrepreneur, Yogev is excited about the integration of software and biology and he is focused on leveraging the integration of the two fields to create disruptive technologies to positively impact human health.

Rick Aldridge, MBChB is Managing Director, Healthcare Investment Banking.

Dr Aldridge is a Chartered Accountant (CA), Chartered Tax Advisor (CTA) and a member of the CFA institute. He holds an MBChB (Medicine) from the University of Edinburgh and a Masters (Dist) in Economic History from the University of Glasgow.

Carl Gordon, PhD, CFA is a Managing Partner and leads OrbiMed’s private equity team. Dr Gordon joined OrbiMed’s predecessor firm in 1995 and was a founding General Partner of OrbiMed in 1998. He did his undergraduate work at Harvard (AB, Chemistry & Physics, 1987), worked at the biotechnology company Imclone Systems (1987-1988), then attained a PhD in Biology from MIT (1993), and was a Postdoctoral Fellow at the Rockefeller University (1993-1995). Carl has been fortunate to have been on the Forbes Midas list of top venture capital investors multiple times. He has founded and invested in numerous biotechnology companies and served on many public and private company boards. When considering investments, Dr Gordon looks for innovative technology and creative management teams and believes the key to success is a combination of integrity, hard work, and passion.

TBA

Dr Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams and drug development consultants, Andy is responsible for driving efficiency and innovation within our scientific organization, both to better serve our customers and drive growth for the Company. Andy has over 15 years of experience in the pharmaceutical and drug delivery industry and is a member of the Academy of Pharmaceutical Scientists of Great Britain. Additionally, Andy has served on the board of directors of the Controlled Release Society, most recently as secretary.

Prior to joining Quotient Sciences, Andy was Director of Novel Drug Delivery Technologies at Ipsen. He holds a Ph.D. in Tissue Engineering and a Bachelor of Pharmacy, both from the University of Nottingham.